Nasus Pharma
6 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis (NCT07228325) | Nasus Pharma | 2025-11-03 |
| FMXIN002 in Patients at Risk of Anaphylaxis (NCT07045701) | Nasus Pharma | 2025-06-12 |
| COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19). (NCT05252468) | Nasus Pharma | 2021-05-19 |
| A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder (NCT04713709) | Nasus Pharma | 2021-01-31 |
| Bioavailability of Nasal Epinephrine (NCT04696822) | Nasus Pharma | 2020-11-01 |
Track Nasus Pharma automatically
Every clearance here is in the API, with alerts when new ones post.